Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics - Wikidata - awgldk - TriplyDB

Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics

Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics

http://www.wikidata.org/entity/Q36354841

about

Current Insights into Long Non-Coding RNAs in Renal Cell Carcinoma The somatic genomic landscape of chromophobe renal cell carcinoma Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels Renal cell carcinoma harboring somatic TSC2 mutations in a child with methylmalonic acidemia Hereditary leiomyomatosis and renal cell carcinoma.Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches.Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer.A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma.Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTPε and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma.Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment.Identification of prognostic genes in kidney renal clear cell carcinoma by RNA‑seq data analysis LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma New strategies in renal cell carcinoma: targeting the genetic and metabolic basis of disease.Sixth BHD Symposium and First International Upstate Kidney Cancer Symposium: latest scientific and clinical discoveries.Recruitment of folliculin to lysosomes supports the amino acid-dependent activation of Rag GTPases Evaluation and screening for hereditary renal cell cancers.A serum-circulating long noncoding RNA signature can discriminate between patients with clear cell renal cell carcinoma and healthy controls.Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management.HGIMDA: Heterogeneous graph inference for miRNA-disease association prediction.Optimal management of metastatic renal cell carcinoma: current status.Hereditary renal cell carcinoma: genetics, clinical features, and surgical considerations.Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial.Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276).The putative tumor suppressor microRNA-30a-5p modulates clear cell renal cell carcinoma aggressiveness through repression of ZEB2.Therapeutic Strategies for Hereditary Kidney Cancer.International cancer seminars: a focus on kidney cancer.PI3Kβ inhibitor TGX221 selectively inhibits renal cell carcinoma cells with both VHL and SETD2 mutations and links multiple pathways.Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact.Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205.Loss of MLH1 confers resistance to PI3Kβ inhibitors in renal clear cell carcinoma with SETD2 mutation.Precision medicine from the renal cancer genome.Renal cell carcinoma: molecular characterization and evolving treatment paradigms.Distribution of glucose transporters in renal diseases.Intratumoral heterogeneity in kidney cancer.NOD2 maybe a biomarker for the survival of kidney cancer patients.Phosphorylation and Ubiquitination Regulate Protein Phosphatase 5 Activity and Its Prosurvival Role in Kidney Cancer.SP1-induced up-regulation of lncRNA SNHG14 as a ceRNA promotes migration and invasion of clear cell renal cell carcinoma by regulating N-WASP.Korean Red Ginseng Extract Enhances the Anticancer Effects of Sorafenib through Abrogation of CREB and c-Jun Activation in Renal Cell Carcinoma.

P2860

Q26752381-86D29450-3A57-43AB-8BC6-7BFC520E9477 Q28246658-ED03FDA2-90DC-4C3D-87A5-88A2C7800735 Q33764288-8C9F4474-B40F-4447-BF06-6B34481781EE Q33792426-3D206698-D972-458B-A021-2B465919D858 Q33817755-C7CB4606-B230-470B-80DA-8B98E4277410 Q33947929-187FB78D-712E-484B-B189-B8CDD7790553 Q34194075-EB08F555-0266-45E8-B512-37754B7AA4BD Q34321254-544DABC8-06D9-4F5E-9F89-C0B5ACD50814 Q34413144-60B1D3D2-B962-453D-8484-B0812FDD0796 Q35934532-F55A83B8-734B-4292-AE26-3021E4060DAF Q36072197-BF093E6A-1368-4F2E-B4D8-10F8D1AF104B Q36297470-CFD928D8-21A8-4B3C-814A-BA5AB1BC4D22 Q36545946-79B6FEF8-FEF3-46C7-8391-292407E92200 Q36642291-4E93F739-4927-4B35-B1A8-A1382F7F991E Q36696610-7117C347-847B-415C-8B3D-93D1A30EC8E5 Q37085770-D7B744E0-90AE-407B-9E41-9CF126C85516 Q37208207-BE9F65E7-5E6D-4830-91DF-052473C84B01 Q37371648-BBD59515-FA9E-4820-8E8C-3564BE8C6A64 Q37499241-77FBED84-A20A-4F5A-8A36-FB0EBFA94A18 Q37549886-BA6605AC-CFA1-461A-B9BC-A678BD84E53C Q37662214-54F805CD-9EB5-4C3E-9D1D-E2DC9594E217 Q38097746-8C811EE3-350C-4B4F-B2B8-B7CCCD1CBBFB Q38202888-728F5E03-8FB5-49D2-988F-8B13854D163B Q38261099-7990EFD6-BEBF-479D-AAB0-39A17E605F09 Q38696543-0554BDC9-DFF8-46A0-BBFD-7CA01A59AB83 Q38751299-A48B73D8-E5A6-445B-B0E2-FF9074F849F5 Q38871343-65127C24-5B28-4EEF-9AFB-11515132084F Q38873586-3A1D2BA2-D012-4E2C-B4CC-DB12A17E6666 Q38889724-B2997CD9-4278-48F2-A5AE-8804DBEE5A03 Q38910995-FB5C5508-EBB7-4F3A-9ECE-17DABB04086B Q38918665-91C7DF79-6943-4BFD-B2AF-E84FC7AB00B5 Q38926738-87F60705-58AF-49D4-9A6A-60CE83622437 Q38970282-F626966C-B3EE-486B-A6B2-5DBCB5FD8366 Q39157961-155CBE01-68FF-4937-BD54-081ED13DC3F1 Q41570521-9551652D-734E-479B-9D13-63163CA28DAF Q42940019-F436FAB1-D75E-4BF4-9A8F-787471126EDD Q47111849-727B59CA-0A7B-45F1-BDBA-226163F82C11 Q47115530-93E5CE07-22C4-4F56-9371-1B7E58A4BDB4 Q47220258-EE653F1E-38D1-427E-A32A-5B3F14E113D7 Q48094297-D22F008A-8F68-4605-B8AF-D5016BDE917B

P2860

Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics

http://www.wikidata.org/entity/Q36354841

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Genetic basis of kidney cancer ...... of disease-based therapeutics

@ast

Genetic basis of kidney cancer ...... of disease-based therapeutics

@en

type

label

Genetic basis of kidney cancer ...... of disease-based therapeutics

@ast

Genetic basis of kidney cancer ...... of disease-based therapeutics

@en

prefLabel

Genetic basis of kidney cancer ...... of disease-based therapeutics

@ast

Genetic basis of kidney cancer ...... of disease-based therapeutics

@en

P1433

Q36354841-CEA52604-4FA8-4F2D-865D-21FD59DDC69A

P1476

Q36354841-1DD4BB24-DA17-4BC6-99BB-33AF7697DB4C

P2093

Q36354841-22003CD3-4409-47DE-9A60-8FFB62BB862E

P2860

Q36354841-03C23874-0EE8-43AB-A222-CBD57ADB00CB

Q36354841-05A2D468-622A-4B96-A335-6288E2E98698

Q36354841-06ED1CE8-A154-44FB-99DC-E515CDD38562

Q36354841-099972CF-5783-49DE-A188-73315ED9B7C1

Q36354841-0B6F6C48-179F-4E2B-A49F-95A1EF270B28

Q36354841-0E88CBA7-69FD-4554-B337-5042E7052E29

Q36354841-0EE06336-70D0-462C-9F6A-0540A6303E42

Q36354841-130A9D0D-F75C-42B3-A559-9E911B24337E

Q36354841-155340DD-DA74-4A30-85FC-50B217F0BB44

Q36354841-16839E64-578B-4B44-BA20-A90169BFA22A

P304

Q36354841-BBC6AC89-6831-42BC-A82C-CB6C61044649

P31

Q36354841-95389E43-62AA-4858-8CB6-1655526D3F6C

P356

Q36354841-B7AFB0F3-DF4C-4363-BB2A-2F42F720D30B

P433

Q36354841-F1AF583B-1183-409F-8687-A8EA1C35D3CC

P478

Q36354841-5DA578CC-FB12-483C-9974-5EE2B7466172

P577

Q36354841-20EED9AD-E383-4EF3-84EE-2F10B66257AA

P5875

Q36354841-449B398B-F361-415C-B824-F87EE5A3A0CD

P698

Q36354841-C8FBF95D-D816-4190-B043-908B79DAD6C5

P932

Q36354841-86BECAA6-B956-4B53-A8A5-9E8395D51DC5

P356

P1433

Genome Research

P1476

Genetic basis of kidney cancer ...... of disease-based therapeutics

@en

P2093

W Marston Linehan

http://www.w3.org/2001/XMLSchema#string

P2860

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling

Identification and characterization of a novel folliculin-interacting protein FNIP2

Inhibition of transcription elongation by the VHL tumor suppressor protein

Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma

Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America

BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports

Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation

Gene expression profiling predicts survival in conventional renal cell carcinoma.

P304

2089-2100

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1101/GR.131110.111

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232088199

http://www.w3.org/2001/XMLSchema#string

P698

23038766

http://www.w3.org/2001/XMLSchema#string

P932

3483538

http://www.w3.org/2001/XMLSchema#string